Introduction
Interleukin-18 (IL-18 (PMID: 42722082)) is a pleiotropic cytokine of the IL-1 superfamily, originally identified in 1995 as "interferon-γ–inducing factor" (IGIF). Unlike most inflammatory cytokines that are rapidly secreted upon synthesis, IL-18 is constitutively expressed as a biologically inert precursor—pro-IL-18—that requires inflammasome-dependent proteolytic processing before acquiring receptor-binding competence. This distinctive biology, combined with its unique regulatory decoy receptor (IL-18 binding protein, IL-18BP), positions IL-18 as a tightly gatekept amplifier of innate-adaptive immune crosstalk.
In research settings, recombinant mature IL-18 serves as a critical reagent for dissecting NK cell activation, Th1 polarization, inflammasome (PMID: 42722082, PMID: 42697481) biology, and the emerging frontiers of engineered cytokine immunotherapy. This profile covers IL-18's molecular architecture, receptor signaling, processing pathways, key regulatory mechanisms, and its evolving role as a research tool in cancer immunology.
This content is provided for Research Use Only (RUO). IL-18 protein is a laboratory reagent intended for in vitro and preclinical research applications. Nothing herein constitutes medical advice or guidance for use in humans or animals.
---
Molecular Structure and Gene Organization
The IL-1 Superfamily Framework
IL-18 (gene: IL18; UniProt Q14116) belongs to the IL-1 cytokine superfamily, sharing the characteristic β-trefoil fold—a twelve-stranded barrel structure formed by three pseudosymmetric β-sheet units. Despite less than 20% amino acid identity with IL-1β, IL-18 adopts a structurally homologous fold that engages an analogous receptor complex through the same IL-1 receptor (IL-1R) superfamily mechanism.
Human pro-IL-18 is a 24 kDa precursor of 193 amino acids. Caspase-1 cleavage at the Asp35–Leu36 bond releases the mature 18 kDa form (157 amino acids) with full biological activity. This N-terminal processing removes a propeptide that sterically occludes receptor-binding surfaces on the β-trefoil scaffold.
Structural Basis of Receptor Recognition
X-ray crystallography and cryo-EM studies have resolved the IL-18/IL-18R1/IL-18RAP ternary complex at atomic resolution. IL-18 engages IL-18R1 (IL-18Rα) through a broad hydrophobic interface involving loops between strands β4–β5, β8–β9, and β11–β12. A second, lower-affinity interaction with IL-18RAP (IL-18Rβ) is required to complete the signaling-competent heterodimeric receptor complex—recapitulating the sequential engagement mechanism shared across the IL-1 superfamily (Kim et al., Nature Communications, 2014).
---
Inflammasome Processing and Secretion
Canonical Caspase-1 Pathway
Pro-IL-18 processing is canonically mediated by caspase-1 activated within multi-protein inflammasome (PMID: 42722082, PMID: 42697481) complexes. Four major inflammasome (PMID: 42722082, PMID: 42697481) sensors drive IL-18 processing:
NLRP3 inflammasome: Assembled in response to danger-associated molecular patterns (DAMPs)—including extracellular ATP, urate crystals, cholesterol crystals, silica, and diverse pathogen-associated triggers. NLRP3 oligomerizes with the ASC adaptor to recruit and auto-activate pro-caspase-1. Active caspase-1 simultaneously cleaves pro-IL-18 and pro-IL-1β, generating the mature bioactive forms.
NLRP1 inflammasome: The evolutionarily oldest NLR-family sensor; in humans, activated by anthrax lethal toxin and ribotoxic stress. NLRP1-driven caspase-1 activation is a major route for IL-18 processing in keratinocytes and intestinal epithelial cells, where pro-IL-18 is constitutively expressed at high levels.
AIM2 inflammasome: Triggered by cytosolic double-stranded DNA through direct binding to the HIN200 domain. Particularly relevant for IL-18 release during viral infection, sterile cell death, and conditions with elevated cytosolic dsDNA.
Pyrin inflammasome: Regulated by Rho GTPase modification status; mutations in pyrin (encoded by MEFV) cause familial Mediterranean fever with episodic dysregulated IL-18 secretion.
Gasdermin D and the Two-Tiered Secretion Model
Caspase-1 simultaneously cleaves gasdermin D (GSDMD), releasing an N-terminal fragment that oligomerizes and forms plasma membrane pores of approximately 10–20 nm diameter. Mature IL-18 egresses through GSDMD pores before full plasma membrane rupture (pyroptosis). This two-tiered secretion model explains why IL-18 can be released without obligate cell death in certain stimulation contexts—pore formation permits cytokine efflux while the cell may reseal transiently.
Non-Canonical and Alternative Processing Pathways
Several non-canonical processing routes expand IL-18 biology beyond the classical inflammasome:
- •Caspase-4/5 (human) and caspase-11 (mouse): Non-canonical inflammasome (PMID: 42722082, PMID: 42697481) activation by cytosolic LPS, leading to GSDMD cleavage and secondary IL-18 release
- •Neutrophil serine proteases: Proteinase 3 and elastase generate extracellular IL-18 fragments with potentially distinct receptor activity profiles
- •Caspase-3 cleavage in cancer cells: A landmark 2024 discovery demonstrated that caspase-3 cleaves pro-IL-18 to generate a distinct 15 kDa short IL-18 that translocates to the nucleus and mobilizes NK cells through a non-classical mechanism independent of IL-18R1 (Nature Immunology, 2024)
---
Receptor Complex and Signal Transduction
IL-18R1 and IL-18RAP: Sequential Engagement Architecture
IL-18 signaling requires assembly of a high-affinity heterodimeric receptor complex:
IL-18R1 (IL-18Rα / CD218a): The primary ligand-binding subunit. Binding of IL-18 to IL-18R1 alone (Kd ~10 nM) is insufficient for productive signaling—it creates a docking interface for the second subunit.
IL-18RAP (IL-18Rβ / CD218b): Recruited after IL-18 binds IL-18R1, the accessory protein dramatically increases binding affinity (Kd ~0.1–1 nM) and contributes the second TIR domain required for intracellular signal initiation. Without IL-18RAP, IL-18R1 binding occurs but no downstream signaling is activated.
Both subunits belong to the IL-1 receptor (IL-1R) family, defined by extracellular immunoglobulin-like domains (IgD1-IgD2-IgD3) and intracellular Toll/IL-1 Receptor (TIR) domains. The IL-18 receptor architecture closely parallels that of IL-1R1/IL-1RAcP and IL-33/ST2/IL-1RAcP complexes.
MyD88–IRAK4–TRAF6–NF-κB Cascade
Upon formation of the IL-18R1/IL-18RAP heterodimer, the juxtaposed TIR domains recruit MyD88 as an adaptor through homotypic TIR–TIR interactions. MyD88 then assembles the Myddosome—a helical signaling tower incorporating IRAK4, IRAK1, and IRAK2—through sequential death domain interactions.
The canonical NF-κB activation cascade:
1. IRAK4 trans-autophosphorylation activates IRAK1
2. IRAK1 phosphorylation permits TRAF6 recruitment
3. TRAF6 (a RING-finger E3 ubiquitin ligase) catalyzes K63-linked polyubiquitin chain assembly
4. TAK1 (MAP3K7) activation via ubiquitin scaffold–TAB2/3 bridging
5. IKK complex (IKKα/IKKβ/NEMO) activation → IκBα Ser32/Ser36 phosphorylation → K48-ubiquitination → proteasomal degradation
6. NF-κB (p65/p50) nuclear translocation → transcription of IFN-γ, pro-inflammatory cytokines, anti-apoptotic Bcl-2 family members, and chemokines
Concurrently, TAK1 activates MAPK cascades (p38-MK2, ERK1/2, JNK), amplifying inflammatory gene expression through AP-1 transcription factor activation and mRNA stabilization via ARE elements (Dinarello et al., Frontiers in Immunology, 2013).
The primary transcriptional output in NK cells and Th1 T cells is IFN-γ, produced synergistically when IL-18 co-signals with IL-12 (discussed below). In macrophages, NF-κB drives a pro-inflammatory gene program including COX-2, iNOS, and additional inflammatory cytokines.
---
IL-18 Binding Protein (IL-18BP): The Unique Decoy Receptor System
Structure, Origins, and Affinity
IL-18BP is a naturally occurring soluble decoy receptor with no transmembrane domain, no kinase activity, and no structural homology to IL-18R1—yet it competes for the same IL-18 binding interface on the β-trefoil scaffold with higher affinity than the membrane receptor. Encoded by IL18BP on human chromosome 11q13, IL-18BP is structurally related to poxviral IL-18-binding proteins (including molluscum contagiosum virus MC54L), suggesting ancient evolutionary entrainment of immune regulatory circuits by viral mimicry (Structural basis IL-18 sequestration, Journal of Biological Chemistry, 202200348-9/fulltext)).
Key affinity parameters:
- •IL-18BP–IL-18 Kd: ~400 pM (picomolar affinity)
- •IL-18R1–IL-18 Kd: ~10 nM (100-fold lower affinity)
This enormous affinity differential means that circulating IL-18BP is essentially undetectable as free protein—virtually all is pre-saturated with IL-18 in physiological conditions. The critical determinant of IL-18 bioavailability is the free IL-18 fraction, calculated from total IL-18, total IL-18BP, and the binding affinity constant.
The IFN-γ/IL-18BP Negative Feedback Loop
The most elegant regulatory feature of IL-18 biology is its self-limiting negative feedback:
IFN-γ (the primary downstream product of IL-18 signaling in NK/T cells) is a potent inducer of IL-18BP transcription and secretion from macrophages, hepatocytes, endothelial cells, and neutrophils. This creates a classical negative feedback circuit:
> IL-18 → IFN-γ production → IL-18BP upregulation → IL-18 neutralization → dampened IFN-γ
This circuit confines IL-18 bioactivity to the local inflammatory milieu, where cell-bound IL-18R1 densities and paracrine concentrations can exceed IL-18BP buffering capacity, while systemic IL-18 remains immunologically inert under physiological conditions.
IL-18BP in Research Applications
IL-18BP serves dual utility in research:
1. Neutralization reagent: Recombinant IL-18BP added at molar excess definitively confirms IL-18-specific effects in complex cytokine-rich supernatants or conditioned media
2. Biomarker context: Paired measurement of total IL-18 and IL-18BP allows calculation of free bioactive IL-18—critical for interpreting disease-state IL-18 biology
---
Cellular Sources and Tissue Expression
Pro-IL-18 is constitutively expressed across diverse cell types—a key distinction from IL-1β, which requires transcriptional NF-κB priming before inflammasome (PMID: 42722082, PMID: 42697481) processing:
| Cell/Tissue Type | Inflammasome Sensor | Research Context |
|---|---|---|
| Macrophages / monocytes | NLRP3, NLRP1 | Primary professional immune source |
| Dendritic cells | NLRP3, AIM2 | Antigen presentation + cytokine licensing |
| Intestinal epithelial cells | NLRP1, NLRP6 | Gut homeostasis; barrier integrity research |
| Keratinocytes | NLRP1 | Epidermal inflammatory biology |
| Kupffer cells (liver) | NLRP3 | Hepatic injury, NASH/MASH models |
| Neutrophils | Caspase-4/5 | IL-18 production + IL-18BP secretion |
| Osteoblasts | NLRP3 | Bone remodeling biology |
---
NK Cell Activation: Synergy with IL-12
The Two-Signal Requirement
Natural killer (NK) cells express among the highest surface densities of IL-18R1/IL-18RAP of any cell type, yet a critical regulatory constraint applies: IL-18 alone does not effectively induce IFN-γ production from resting NK cells.
IL-18 functions as a co-stimulatory amplifier that synergizes obligately with IL-12:
| Stimulus | IFN-γ Output (relative) |
|---|---|
| IL-12 alone (10 ng/mL) | Moderate (baseline reference) |
| IL-18 alone (100 ng/mL) | Minimal (2–3× baseline) |
| IL-12 + IL-18 combined | Massive (>100× synergistic) |
IL-12 activates STAT4 through IL-12Rβ2, which transcriptionally upregulates IL-18R1 expression on NK cells and T cells. This receptor upregulation amplifies IL-18 responsiveness—creating a positive feedforward loop where IL-12 licensing maximizes NK cell sensitivity to IL-18. The dual-signal requirement prevents aberrant NK activation from isolated innate danger signals alone ([Okamura et al., Immunity, 1998]()).
Full NK Cell Activation Program
Beyond IFN-γ induction, IL-18 (with IL-12 co-stimulation) drives a comprehensive NK activation program in research models:
- •Cytokine production: TNF-α, GM-CSF, IL-3, IL-8 (CXCL8)
- •Death ligand upregulation: FasL (CD95L), TRAIL—enhancing NK cytotoxicity against Fas+ and TRAIL-R+ targets
- •Granule exocytosis: Enhanced perforin and granzyme B degranulation (measured by CD107a surface exposure)
- •Proliferative expansion: Synergistic with IL-2 for NK cell numerical expansion in culture
- •Chemokine receptor reshaping: CCR2 upregulation, facilitating NK trafficking to inflammatory sites
These properties make the IL-12/IL-18 combination the gold-standard protocol for maximal ex vivo NK cell activation in functional assays examining cytotoxicity, degranulation (CD107a), ELISPOT IFN-γ quantification, and phenotypic maturation.
---
Th1 Polarization and Adaptive Immune Effects
In naive CD4+ T cells, IL-18R1 surface expression is low but inducible by IL-12. This creates a sequential licensing mechanism:
1. IL-12 → STAT4 activation → IL-18R1 transcription → IL-18R1 surface expression
2. IL-18 → NF-κB activation → IFN-γ gene transcription + T-bet stabilization
3. IFN-γ → STAT1 activation → further IL-12Rβ2 and T-bet expression (positive feedback)
Together, IL-12 and IL-18 cooperatively drive Th1 polarization far more potently than either alone. IL-18 does not independently determine Th1 fate but amplifies and stabilizes Th1 commitment through NF-κB–dependent IFN-γ production.
A critical contextual dependency: in the absence of IL-12, high IL-18 can paradoxically promote Th2 responses (IL-4, IL-13) and IgE class switching in mast cells and basophils. This pleiotropism reflects cell-type-specific receptor expression landscapes and co-stimulatory signal integration—a nuance critical for interpreting IL-18 effects in mixed-cell system research.
---
Disease Biology: Research Model Insights
Macrophage Activation Syndrome and HLH
MAS and hemophagocytic lymphohistiocytosis (HLH) represent the most dramatic manifestations of IL-18 dysregulation. Defining characteristics of MAS include:
- •Total serum IL-18: >100,000 pg/mL (vs. <100 pg/mL in healthy individuals)
- •IL-18BP does not sufficiently buffer extreme IL-18 elevation
- •Detectable free IL-18 circulates and drives systemic NK/macrophage hyperactivation
Research using CpG-oligodeoxynucleotide–induced MAS mouse models demonstrated that NLRP3 inflammasome (PMID: 42722082, PMID: 42697481) activation drives IL-18 processing critical for MAS pathogenesis, and NLRP3 inhibition markedly attenuates severity (Girard-Guyonvarc'h et al., PMC, 2024). IL-18BP knockout mice show dramatically exacerbated MAS with worsened anemia and cytopenias, directly demonstrating IL-18BP's protective buffering role.
Adult-Onset Still's Disease (AOSD)
IL-18 has emerged as the defining biomarker of AOSD, an autoinflammatory condition of systemic inflammation. Serum IL-18 in active AOSD can exceed 500,000 pg/mL, vastly surpassing levels in other inflammatory conditions. The IL-18/IL-18BP ratio—rather than total IL-18 alone—correlates most closely with disease activity and the risk of MAS complication (Autoinflammatory disease IL-18 review, Frontiers in Immunology, 2023).
Inflammatory Kidney Disease Research
IL-18 has emerged as a sensitive biomarker and pathogenic mediator in acute kidney injury (AKI). In ischemia-reperfusion injury models, renal tubular epithelial cells release pro-IL-18 that is processed by locally activated NLRP3 inflammasomes, driving tubular inflammation and propagating injury beyond the initial ischemic zone. Urinary IL-18 elevation precedes serum creatinine rise in early AKI, making it a research tool for dissecting injury kinetics (IL-18 in inflammatory kidney disease, PMC, 2021).
---
Cancer Immunotherapy Research: Emerging Frontiers
IL-18BP–Mediated Immune Evasion in Tumors
The tumor microenvironment (TME) co-opts the IL-18/IL-18BP regulatory axis for immune evasion. Tumor cells and tumor-associated macrophages (TAMs) secrete IL-18BP, creating an immunosuppressive milieu that neutralizes NK cell-activating IL-18 signals and contributes to NK cell dysfunction within the TME. Overcoming this TME-specific IL-18 decoy inhibition has become a target for engineered cytokine approaches.
Decoy-Resistant IL-18 (DR-18) Engineering
Through structure-guided mutagenesis of IL-18's IL-18BP-contact interface, researchers engineered DR-18—a variant that retains full IL-18R1/IL-18RAP engagement but escapes IL-18BP neutralization. Key research findings:
- •DR-18 resists inhibition even at super-physiological IL-18BP concentrations
- •In syngeneic solid tumor models (renal cell carcinoma, sarcoma), DR-18 demonstrates superior anti-tumor activity versus wild-type IL-18
- •DR-18 reshapes the TME toward inflammatory phenotypes: increased NK/CD8+ T cell infiltration, elevated IFN-γ, reduced regulatory T cell frequency (DR-18 in renal cell carcinoma, JCI Insight, 2024)
- •Fc-fusion half-life extension combined with IL-18BP resistance (NCT06492707) represents current clinical translation strategy
IL-18-Armored CAR T Cells
Constitutive IL-18 secretion has become a leading "armoring" strategy for CAR T cell engineering:
CD19-targeting CAR T cells with IL-18: In preclinical lymphoma models, IL-18-secreting CAR T cells showed enhanced persistence, reduced exhaustion marker expression (PD-1, LAG-3, TIM-3), and superior tumor control versus unarmed CAR T cells—even against tumors with heterogeneous antigen expression.
Multiantigen-targeting IL-18-armored CAR T cells: Demonstrated elimination of antigen-low myeloma that escapes unarmed CAR T cell attack, by remodeling the TME to promote bystander cytotoxicity (Blood, 2024).
GD2-targeting with inducible IL-18: Antigen-inducible (rather than constitutive) IL-18 secretion in GD2-CAR T cells reduces systemic cytokine exposure while maintaining local TME remodeling in solid tumor models.
Active research is characterizing the risk-benefit profile of IL-18 armoring, particularly regarding cytokine release syndrome augmentation and potential autoimmune sequelae (Risk-benefit review IL-18 CAR T, PMC, 2025).
Short IL-18: The Nuclear Isoform
The 2024 discovery of caspase-3–generated nuclear short IL-18 revealed an entirely new dimension of IL-18 biology with direct anti-tumor implications. In cancer cells undergoing apoptosis, caspase-3 cleaves pro-IL-18 at a distinct site, generating a 15 kDa fragment that:
1. Lacks the canonical IL-18R1-binding epitopes of mature IL-18
2. Translocates to the nucleus via a nuclear localization signal
3. Enhances NK cell mobilization and cytotoxic function through a non-receptor-dependent mechanism
Colorectal cancer patients with high nuclear short IL-18 in tumor cells demonstrate improved prognosis—suggesting a cell-intrinsic anti-tumor immune signaling function distinct from extracellular IL-18R1 pathway activation (Short IL-18, Nature Immunology, 2024). This discovery opens new avenues for understanding how dying cancer cells communicate with the immune system.
---
Research Reagent Considerations
In Vitro Protocol Reference
| Assay | Recombinant IL-18 Concentration | Notes |
|---|---|---|
| NK cell IFN-γ induction | 10–100 ng/mL + IL-12 (10 ng/mL) | Measure IFN-γ by ELISA at 18–24h |
| CD4+ Th1 polarization | 10–50 ng/mL + IL-12 (10 ng/mL) | 5–7 day culture with anti-CD3/28 |
| PBMC activation | 10 ng/mL (alone or + IL-12) | Total PBMC; measure NK and T responses |
| NF-κB reporter (HEK293 cells) | 0.1–100 ng/mL dose-response | Requires transfection of IL-18R1 + IL-18RAP |
| IL-18BP neutralization control | Molar excess IL-18BP vs. IL-18 | Confirms IL-18 specificity in complex systems |
Distinguishing IL-18 from IL-1β in Research Systems
Despite sharing the IL-1 superfamily β-trefoil fold and MyD88/NF-κB signaling axis, IL-18 and IL-1β have distinct experimental footprints:
| Feature | IL-18 | IL-1β |
|---|---|---|
| Primary target cells | NK cells, Th1 T cells | Stromal cells, endothelium, hepatocytes |
| Fever induction | No (no PGE2 induction at hypothalamic level) | Yes (potent pyrogen) |
| Decoy receptor | IL-18BP (soluble, picomolar affinity) | None (IL-1Ra is competitive receptor antagonist) |
| Synergistic partner | IL-12 (for IFN-γ induction) | IL-6 (for acute phase response) |
| Pro-form expression | Constitutive in most tissues | Requires NF-κB priming first |
| Processing | Caspase-1 (Asp35↓Leu36) | Caspase-1 (Asp116↓Ala117) |
Simultaneous detection of both cytokines in inflammasome (PMID: 42722082, PMID: 42697481) biology research provides complementary information about activation specificity, caspase engagement, and pyroptosis kinetics.
Quality Attributes for Research-Grade IL-18
- •Endotoxin content: <1 EU/μg (critical for avoiding LPS-driven IL-12 induction that confounds NK activation assays)
- •Correct cleavage site: Asp35↓Leu36 generates authentic mature IL-18; N-terminal sequencing validates authentic processing
- •IL-18BP competition assay: SPR-based Kd measurement against recombinant IL-18BP confirms receptor-binding competence
- •Bioactivity validation: NK cell IFN-γ induction assay (with IL-12 co-stimulation) provides the gold-standard functional readout
---
Summary and Research Landscape
IL-18 occupies a singular position among cytokine research reagents: constitutively expressed yet tightly gatekept, pleiotropic yet contextually constrained by IL-18BP, and increasingly central to the frontiers of engineered cancer immunotherapy. Its dual-signal requirement with IL-12 for maximal NK cell activation, the elegant IFN-γ/IL-18BP negative feedback system, and its pathognomonic elevation in MAS/HLH and AOSD make it an exceptionally informative probe for innate-adaptive immune crosstalk.
The 2024–2025 emergence of decoy-resistant IL-18 variants entering clinical investigation, IL-18-armored CAR T cell programs demonstrating preclinical efficacy in refractory hematological malignancies, and the discovery of the nuclear caspase-3-generated short IL-18 isoform have substantially expanded the scientific landscape. For laboratories studying cancer immunology, inflammasome (PMID: 42722082, PMID: 42697481) biology, cytokine storm pathophysiology, or NK and T cell functional biology, recombinant IL-18 and its engineered derivatives represent essential and dynamically evolving research tools.
Related research profiles on this platform: IL-12 (Interleukin-12) | IL-15 (Interleukin-15) | IL-33 (Interleukin-33) | IL-1β (Interleukin-1 Beta)
---
Research Use Only. IL-18 cytokine is a laboratory reagent for in vitro and preclinical research investigations. Not for diagnostic, therapeutic, or use in humans or animals. All experimental work should comply with applicable biosafety regulations and institutional guidelines.